Skip to main content

Table 2 Summary of MS History (Full Analysis Set)

From: Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study

 

n

mean ± sd

median

min-max

Years since MS diagnosis

64

2.1 ± 4.00

0.2

0.04–14.3

Mean number of relapses within the last 24 months prior to Rebif® Rebismart™ initiation

62

1.5 ± 0.76

1.0

0–4

Mean number of relapses in which corticosteroids were usedwere used were used

62

0.9 ± 0.71

1.0

0–3

Mean number of relapses within the last 12 months prior to Rebif® Rebismart™ initiation

63

1.1 ± 0.47

1.0

0–2

Mean number of relapses in which corticosteroids were used

62

0.9 ± 0.57

1.0

0–2